Brett Monia, Ionis CEO

Io­n­is touts PhII MASH study da­ta that fea­ture its DGAT2 an­ti­sense in­hibitor

Io­n­is said on Wednes­day that its meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis (MASH) drug hit the pri­ma­ry and sec­ondary end­points of a Phase II tri­al, no­tably show­ing his­to­log­ic im­prove­ment and MASH res­o­lu­tion.

The drug, a DGAT2 an­ti­sense in­hibitor dubbed ION224, was test­ed at 120 mg and 90 mg in 160 pa­tients across 49 weeks. Io­n­is used the NAFLD Ac­tiv­i­ty Score to mea­sure liv­er his­to­log­ic im­prove­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.